Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of its short-term Phase 3 study of Zerenex (ferric citrate), the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE